A Randomized Double-masked, Multicenter, 3-arm, Pivotal Phase 2/3 Study to Evaluate the Efficacy and Safety of Intravitreal (IVT) EYE201/MK-8748 Compared to Aflibercept (2 mg) in Participants With Neovascular Age-related Macular Degeneration (NVAMD)
A Randomized Double-masked, Multicenter, 3-arm, Pivotal Phase 2/3 Study to Evaluate the Efficacy and Safety of Intravitreal (IVT) EYE201/MK-8748 Compared to Aflibercept (2 mg) in Participants With Neovascular Age-related Macular Degeneration (NVAMD)
Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD).
Available standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person. Researchers want to learn if a trial medicine called tiespectus (also called MK-8748 or EYE201) can treat NVAMD.
The goal of this trial is to learn if tiespectus works as well as aflibercept to treat NVAMD.
The main inclusion criteria include but are not limited to the following:
The main exclusion criteria include but are not limited to the following
Trialsites@msd.com1-888-577-8839
Gilbert, Arizona 85259, United States
602-242-4928
Mountain View, California 94040, United States
Winter Haven, Florida 33880, United States
Springfield, Massachusetts 01107, United States
Great Neck, New York 11021, United States
Asheville, North Carolina 28803, United States
São Paulo, 04038-032, Brazil
Udine, 33100, Italy
jesusv@theretinapartners.com818-788-9333 ext. 1141
650-963-3465
714-972-8432
719-473-9595
720-443-2425
719-473-9595
203-791-2020
860-646-7704
860-444-1292
239-938-1284
407-849-9621
941-924-0303
863-297-5400 ext. 2020
815-744-7515
708-765-4110
515-223-8686
913-831-7400
502-589-1500
207-523-5548
301-671-2400
413-732-2333
952-259-6262
973-707-5632 ext. 1124
516-466-0390
585-450-2082
828-255-8008 ext. 2824
asmith@ncretina.com919-782-8038
828-304-6643
asmith@ncretina.com919-782-8038
503-371-4350
541-687-1927
814-200-9152
843-763-4466 ext. 1404
803-931-0077
843-763-4466
803-744-0158
kschratter@seretina.com423-756-1002
423-578-4364
865-588-0811
615-983-6000
713-394-7576
817-334-0882 ext. 405
713-524-3434
800-252-8259
210-903-1046 ext. 2051
512-451-0103
210-693-1063
801-679-4173
540-342-3400
206-215-3850
920-751-8666
5511 3016-4096
57 3043909153
57 3108790322
57 3004764838
57 3136997380
420731542840
420775270681
420 602171106
420724728981
420 267162913
(+33) 1 570 23068
+33 4 91 16 05 84
(+33) 6 2633 1609
+36-30-230-9177
(+39) 0432 559905
351 239 480127
00 351 965439405
(+34)937071936
(+34)674757868